The market size for infectious disease diagnostics is expected to grow at a steady pace, reaching USD 21.5 billion in 2024. It is estimated that this positive trend will continue, with the market reaching USD 43.2 billion by 2034. Based on these estimates, a CAGR of 7.2% is expected over the next decade.
The adoption of POCT devices for infectious disease diagnostics is expected to grow significantly. These portable and easy-to-use devices allow for rapid diagnostics at the bedside or in remote settings, facilitating timely diagnosis and treatment initiation.
POCT will continue to gain traction, particularly in resource-limited areas and during outbreaks where access to centralized laboratories is limited. The integration of AI and machine learning algorithms into diagnostic platforms will streamline data analysis, interpretation, and decision-making processes.
AI-powered diagnostic tools will enhance accuracy, efficiency, and scalability, revolutionizing infectious disease diagnostics and surveillance.
Molecular diagnostics, including PCR and NGS-based assays, will remain at the forefront of infectious disease diagnostics. The ability of these tests to detect pathogens with high sensitivity and specificity makes them indispensable in clinical practice and public health settings.
As the global burden of infectious diseases continues to rise, there will be a growing demand for molecular diagnostic tests for early detection and monitoring.
With the ongoing threat of emerging infectious diseases and the rise of antimicrobial resistance, there will be increased emphasis on developing diagnostic tests for newly identified pathogens and drug-resistant strains.
Public health efforts will prioritize surveillance, early detection, and containment of emerging threats, driving investment in novel diagnostic solutions.
| Attributes | Details |
|---|---|
| Infectious Disease Diagnostics Market Size (2024E) | USD 21.5 billion |
| Infectious Disease Diagnostics Market Projected Size (2034F) | USD 43.2 billion |
| Value CAGR (2024 to 2034) | 7.2% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
The increasing incidence of infectious diseases such as COVID-19, HIV, tuberculosis, malaria, and influenza has heightened the demand for effective diagnostic tools. This surge is largely due to the global rise in population, increased travel, and urbanization, which facilitate the spread of infections.
Innovations in diagnostic technologies, including molecular diagnostics, polymerase chain reaction (PCR), next-generation sequencing (NGS), and point-of-care (POC) testing, have revolutionized the market. These technologies offer rapid, accurate, and early detection of pathogens, which is crucial for effective disease management and control.
Governments worldwide are investing heavily in healthcare infrastructure and disease surveillance programs. Funding for research and development in infectious disease diagnostics is increasing, driven by the need to prepare for and respond to pandemics and other infectious disease outbreaks.
Public awareness regarding the importance of early detection and diagnosis of infectious diseases is growing. This awareness is supported by healthcare campaigns and educational programs, which emphasize the benefits of early intervention in managing and controlling disease spread.
Rising healthcare expenditure globally is enabling better access to advanced diagnostic tools and services. This is particularly evident in developing countries where improving healthcare infrastructure is a priority, thereby boosting the adoption of infectious disease diagnostics.
Globalization has led to increased travel and trade, contributing to the spread of infectious diseases across borders. This has created a heightened need for robust diagnostic systems to monitor and control outbreaks, especially at ports of entry and among travelers.
The global aging population is more susceptible to infections due to weakened immune systems. As a result, there is a higher demand for diagnostic testing among the elderly, driving market growth.
The emergence of new and re-emerging pathogens, such as the Ebola virus, Zika virus, and most recently, SARS-CoV-2, necessitates the development and deployment of new diagnostic tests. The dynamic nature of pathogens requires continuous innovation in diagnostic approaches.
The increasing preference for point-of-care testing, which provides rapid results and can be conducted outside traditional laboratory settings, is a significant driver. This trend is particularly important in remote and underserved areas where access to centralized laboratories is limited.
The private sector is playing a crucial role in the development of new diagnostic technologies. Pharmaceutical and biotechnology companies are investing in research and development to create more effective and user-friendly diagnostic tools, driven by the lucrative potential of the market.
The infectious disease diagnostics market in the United States benefits from a highly competitive and innovative landscape. A major factor is the robust infrastructure of the Centers for Disease Control and Prevention (CDC), which plays a critical role in disease surveillance and outbreak response.
The United States market is also distinguished by strong collaborations between academic institutions, biotechnology firms, and government agencies, fostering an environment ripe for innovation.
The extensive insurance coverage and reimbursement policies in the United States further encourage advances in rapid infectious disease diagnostics.
Moreover, the presence of large healthcare conglomerates and a mature market for clinical trials allow for the rapid development and deployment of new diagnostic tools. Public awareness campaigns about the importance of diagnostics in disease prevention and management also drive market growth.
China's infectious disease diagnostics market is rapidly expanding, driven by the country's large population and the increasing incidence of infectious diseases such as tuberculosis, hepatitis, and emerging viral infections.
The Chinese government’s proactive approach to healthcare reform and infectious disease control has led to substantial investments in healthcare infrastructure and diagnostic technologies.
The market is characterized by the adoption of advanced diagnostic tools, including molecular diagnostics and rapid testing methods. Public health policies, such as the national tuberculosis control program and extensive screening for infectious diseases, significantly boost market demand. Additionally, China's growing biotechnology sector and the presence of numerous domestic diagnostic companies contribute to the market's dynamism.
The government’s focus on enhancing healthcare access in rural and underserved areas also plays a critical role in promoting the future of point-of-care infectious disease testing and other innovative diagnostic solutions across the country.
In the United Kingdom, the market for infectious disease diagnostics is notably influenced by the centralized healthcare system provided by the National Health Service (NHS).
This centralized system ensures that new diagnostic technologies can be integrated uniformly across the country, leading to widespread and equitable access. The United Kingdom also places a strong emphasis on public health and preventive measures, supported by entities such as Public Health England.
The United Kingdom's participation in international health initiatives and collaborations, especially with the European Centre for Disease Prevention and Control, enhances its diagnostic capabilities.
Additionally, the United Kingdom government’s focus on antimicrobial resistance (AMR) has led to significant investments in diagnostics aimed at identifying resistant strains of pathogens, thus guiding appropriate treatment strategies. The strong regulatory framework in the United Kingdom also ensures the safety and efficacy of diagnostic tests.
Principal Consultant
PCR tests are renowned for their high sensitivity and specificity, which allows for the accurate detection of even minute quantities of pathogen DNA or RNA. This precision is crucial for diagnosing infections early, often before symptoms appear, leading to timely and effective treatment.
PCR tests provide rapid results compared to traditional culture-based methods, which can take days to yield outcomes. This speed is vital for controlling outbreaks and implementing timely public health interventions. The ability to quickly confirm or rule out infections helps in managing patient care more efficiently and reduces the spread of contagious diseases.
Advancements in PCR technology, such as real-time PCR (qPCR) and digital PCR (dPCR), have further enhanced its capabilities. Real-time PCR provides quantitative data, which is useful for monitoring viral loads in patients, while digital PCR offers even greater precision and sensitivity. These technological improvements have expanded the applications and reliability of PCR tests, driving their adoption in clinical settings.
There is a growing demand for accurate and reliable diagnostic tests due to rising awareness about the importance of early detection and treatment of infectious diseases. PCR tests meet this demand by providing precise and dependable diagnostic results, contributing to their increased use in healthcare settings.
Assays and reagents play a critical role in expanding the test menu for infectious disease diagnostics. Manufacturers are developing multiplex assays capable of detecting multiple pathogens simultaneously, providing comprehensive testing solutions for syndromic panels and respiratory infections. This versatility enhances diagnostic efficiency and streamlines laboratory workflows.
Advancements in assay development allow for customization and tailoring of diagnostic tests to individual patient needs.
Assays and reagents can be optimized for specific pathogens, genetic variations, and antimicrobial resistance markers, supporting personalized medicine approaches. This customization enhances diagnostic accuracy and guides more effective treatment strategies.
Investments in research and development (R&D) are driving innovation in assay technologies and reagent formulations. Manufacturers are investing in novel platforms, such as digital PCR, loop-mediated isothermal amplification (LAMP), and CRISPR-based assays, to enhance sensitivity, specificity, and speed of diagnostics. These advancements expand the market potential and address unmet needs in infectious disease testing.
Leading companies in the infectious disease diagnostics market are employing several strategies to foster growth. These include investing in research and development to innovate new diagnostic technologies expanding their product portfolios to offer a comprehensive range of testing solutions.
In addition, they are forging strategic partnerships and collaborations with other industry players or healthcare institutions, enhancing market presence through mergers and acquisitions, and focusing on geographic expansion to tap into emerging markets.
Additionally, players are prioritizing customer education and support to increase awareness and adoption of their diagnostic products and services, ultimately driving market growth and profitability.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
In terms of product, the market encompasses assays & reagents, instruments, and software.
Based on disease types, the market is categorized into hepatitis, human immunodeficiency virus, influenza, and others.
The technology segment comprises immunodiagnostics, clinical microbiology, polymerase chain reaction, and next-generation sequencing.
As per region, the industry is divided into North America, Latin America, Western Europe, South Asia, East Asia, Eastern Europe, and the Middle East and Africa.
A market value of USD 21.5 billion is expected for infectious disease diagnostics by 2024.
A market valuation of USD 43.2 billion is expected by 2034 for infectious disease diagnostics.
The value of CAGR for the infectious disease diagnostics market is estimated to be 7.2%.
The assays & reagents segment will garner a significant market value share by 2024.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis 2019 to 2023 and Forecast 2024 to 2034, including Historical Analysis and Future Projections 5. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034 5.1. Product 5.2. Disease Type 5.3. Technology 6. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Product 6.1. Assays & Reagents 6.2. Instruments 6.3. Software 7. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Disease Type 7.1. Hepatitis 7.2. Human Immunodeficiency Virus 7.3. Influenza 7.4. Others 8. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Technology 8.1. Immunodiagnostics 8.2. Clinical Microbiology 8.3. Polymerase Chain Reaction 8.4. Next Generation Sequencing 8.5. Others 9. Global Market Analysis 2019 to 2023 and Forecast 2024 to 2034, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. South Asia 9.5. East Asia 9.6. Eastern Europe 9.7. Middle East & Africa 10. North America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 11. Latin America Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 12. Western Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 13. South Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 14. East Asia Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 15. Eastern Europe Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 16. Middle East & Africa Sales Analysis 2019 to 2023 and Forecast 2024 to 2034, by Key Segments and Countries 17. Sales Forecast 2024 to 2034 by Product, Disease Type, and Technology for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. Biomérieux SA 19.2. Abbott Laboratories 19.3. Becton, Dickinson and Company 19.4. Bio-Rad Laboratories 19.5. Danaher Corporation 19.6. F. Hoffmann-La Roche AG 19.7. Siemens Healthineers 19.8. Thermo Fisher Scientific 19.9. Quidel Corporation 19.10. DiaSorin SpA (Luminex) 19.11. Trinity Biotech PLC
Explore Healthcare Insights
View Reports
Infectious Disease Diagnostics Market
